Title (en)

4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS

Title (de)

4-AZASTEROID-DERIVATE ALS ANDROGEN-REZEPTOR-MODULATOREN

Title (fr)

DERIVES DE 4-AZASTEROIDE UTILISES COMME MODULATEURS DU RECEPTEUR DE L'ANDROGENE

Publication

EP 1501512 A4 20091118 (EN)

Application

EP 03719957 A 20030425

Priority

- US 0313120 W 20030425
- US 37677902 P 20020430

Abstract (en)

[origin: WO03092588A2] Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer s disease, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

IPC 8 full level

A61K 31/56 (2006.01); **C07J 73/00** (2006.01); **A61K 31/568** (2006.01); **A61P 1/02** (2006.01); **A61P 3/04** (2006.01); **A61P 3/06** (2006.01); **A61P 5/26** (2006.01); **A61P 7/06** (2006.01); **A61P 9/10** (2006.01); **A61P 15/10** (2006.01); **A61P 15/12** (2006.01); **A61P 17/00** (2006.01); **A61P 19/02** (2006.01); **A61P 19/08** (2006.01); **A61P 19/10** (2006.01); **A61P 21/00** (2006.01); **A61P 21/04** (2006.01); **A61P 25/28** (2006.01); **A61P 31/18** (2006.01); **A61P 35/00** (2006.01); **A61P 37/02** (2006.01)

CPC (source: EP US)

A61P 1/02 (2017.12 - EP); **A61P 3/04** (2017.12 - EP); **A61P 3/06** (2017.12 - EP); **A61P 5/26** (2017.12 - EP); **A61P 7/06** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 15/10** (2017.12 - EP); **A61P 15/12** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 19/08** (2017.12 - EP); **A61P 19/10** (2017.12 - EP); **A61P 21/00** (2017.12 - EP); **A61P 21/04** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 31/18** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/02** (2017.12 - EP); **C07D 221/18** (2013.01 - EP US); **C07D 403/02** (2013.01 - EP US); **C07J 73/005** (2013.01 - EP US)

Citation (search report)

- [XY] WO 9507926 A1 19950323 - GLAXO INC [US], et al
- [TY] WO 9825623 A1 19980618 - MERCK & CO INC [US], et al
- See references of WO 03092588A2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

Designated extension state (EPC)

LT LV

DOCDB simple family (publication)

WO 03092588 A2 20031113; **WO 03092588 A3 20040715**; AU 2003223754 A1 20031117; AU 2003223754 B2 20070816; CA 2484173 A1 20031113; EP 1501512 A2 20050202; EP 1501512 A4 20091118; JP 2005529897 A 20051006; JP 4516839 B2 20100804; US 2005131005 A1 20050616; US 2006281761 A1 20061214; US 7625919 B2 20091201

DOCDB simple family (application)

US 0313120 W 20030425; AU 2003223754 A 20030425; CA 2484173 A 20030425; EP 03719957 A 20030425; JP 2004500773 A 20030425; US 50432506 A 20060814; US 51280004 A 20041027